文献速递肿瘤 PET/CT

PET/CT在恶性胸膜间皮瘤疗效评估中的现状与未来展望

Current and Future Perspective of PET/CT in Response Assessment of Malignant Pleural Mesothelioma.
PubMed 文献 · Semin Nucl Med · 2025-02-27

本文综述了PET/CT在恶性胸膜间皮瘤疗效评估中的作用。随着治疗向免疫治疗转变,疗效评估愈发复杂,近期研究提示FDG PET/CT可能比传统CT提供更有效的疗效标准。本文强调PET/CT在深入洞察疾病状态和监测治疗反应方面的重要作用,并讨论当前影像标准的挑战、FDG摄取的非特异性以及新兴放射性药物和先进容积评估的潜力。

要点

  • FDG PET/CT可能比传统CT提供更有效的疗效评估标准。
  • FDG摄取可能反映治疗后炎症而非肿瘤活性,影响评估特异性。
  • 新兴放射性药物和先进容积评估有望提高诊断准确性和治疗评估。

核心结论

  • PET/CT在深入洞察疾病状态和监测治疗反应方面具有重要作用。
  • 近期研究提示FDG PET/CT可能比传统CT提供更有效的疗效标准。

研究设计与样本

  • 本文为综述,检索范围未在原文中报告。

主要发现

  • 随着MPM治疗向免疫治疗转变,疗效评估变得愈发复杂。
  • FDG摄取可能代表治疗后或操作后的炎症反应而非肿瘤活性,影响评估特异性。
  • 新兴放射性药物和先进容积评估可能改善MPM的诊断准确性和治疗评估。

局限性

  • 当前影像标准存在挑战,尤其FDG摄取的非特异性可能代表炎症反应而非肿瘤活性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Malignant pleural mesothelioma (MPM) is a rare but aggressive cancer characterized by its unique growth patterns, presenting substantial diagnostic challenges. With the shift toward immunotherapy for MPM treatment, assessing therapeutic responses has become increasingly complex. Recent studies indicate that FDG PET/CT may provide more effective response criteria compared to traditional CT-based methods. This review emphasizes the important role of PET/CT in offering deep insights into the disease state and monitoring treatment responses. It also addresses the challenges associated with current imaging criteria, particularly the nonspecificity of FDG uptake that may represent inflammatory responses following treatments or procedures rather than tumor activity. Furthermore, the review discusses the potential of emerging radiopharmaceuticals and advanced volumetric assessments, discussing their implications for improving diagnostic accuracy and treatment evaluation in MPM.

来源:Semin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Badarna M, Keidar Z, Arnon-Sheleg E, et al. Current and Future Perspective of PET/CT in Response Assessment of Malignant Pleural Mesothelioma. Semin Nucl Med. 2025. PMID: 40021361. doi:10.1053/j.semnuclmed.2025.02.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。